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1. Introduction 
Various biological functions of Boron (B) compounds are known (Blevins & Lukaszewski, 
1994; Tariq & Mott, 2007; Nielsen, 2008). Boron is found in nuts, vegetables, dried/fresh 
fruits and red wine (Brown & Shelp, 1997). Boron is also present in bacterial antibiotics, 
such as tartrolon, borophycin, boromycin and aplasmomycin (Rezanka & Sigler, 2008); in 
the bacterial quorum sensing molecule auto-inducer AI-2 (Bemd et al., 2002); and in 
vibrioferrin, a B-containing siderophore produced by particular marine bacteria (Shady et 
al., 2007). In plants, the rigidity of the cell wall depends on the rhamnogalacturonan II 
complex (RG-II) formation, a pectic polysaccharide covalently linked by cis-diol bonds to 
apiosil residues of borate-esters (Ishii & Matsunaga, 1996, 2001). Several articles have 
provided information about transporters responsible for efficient B uptake by roots, xylem 
loading and B distribution among leaves. The transporters are required under B limitation 
for efficient acquisition and utilisation of B. Two types of transporters are involved in 
these processes: NIPs (nodulin-26-like intrinsic proteins) for boric acid channels and 
boron exporters encoded by BOR1 (Miwa & Fujiwara, 2010). The expression of the genes 
encoding these transporters has been shown to be finely regulated in the B availability 
response to ensure tissue B homeostasis. Furthermore, the tolerance of plants to the stress 
produced by low B or high B in the environment can be generated by altering the 
expression of these transporters (Tanaka & Fujiwara, 2007). All of these transporters are 
involved in boron transport regulation in plants. B is an essential element not only for 
vascular plants but also for diatoms, cyanobacteria and a number of marine algal 
flagellate species (Rezanka & Sigler, 2008). Recently, ATR1 has been found to be 
responsible for the high B tolerance in S. Cerevisiae. ATR1 encodes a multidrug resistance 
transporter and it is widely distributed in bacteria, archaea and lower eukaryotes (Miwa & 
Fujiwara, 2010). Animals such as zebra, fish, trout and frogs also require boron (Rowe & 
Eckert, 1999; Fort et al., 1999). Borate ions activate the mitogen-activated protein kinases 
pathway and stimulate the growth and the proliferation of human embryonic kidney 293 
cells (Park et al., 2005). The B-transporter, NaBCl, controls plasma borate levels in human 
kidney cells (Park at al., 2004). The fact that B has such a broad range of physiological 
functions is not surprising. The electron structure of B and its position in the periodic 
table (adjacent to carbon) make B-containing molecules electrophilic with the trigonal  
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planar structures that are isoelectronic neutral relative to carbocations. The additional 
bond with B allows the formation of anionic tetravalent compounds with tetrahedral 
structures, which behave as nucleophiles (Petasis, 2007). Various types of B-containing 
molecules already exist and have been investigated as therapeutic agents. These 
molecules include B-containing analogues of natural biomolecules (Morin, 1994), the 
antibacterial and antimalarial agent diazaborine (Baldock et al., 1998), antibacterial 
oxazaborolidines (Jabbour et al., 2004; Jabbour et al., 2006), antibacterial diphenyl borinic 
esters (Benkovic et al., 2005), the antifungal agent benzoxaborole AN2690 (Baker et al., 
2006) and a B-N bond containing an estrogen receptor modulator (Zhou et al., 2007). 
Except for the drug Bortezomib, the majority of B compounds currently used in cancer 
treatment are in the Neutron Capture Therapy (BNCT) class (Beddoe, 1997; Endo et al., 
2003). The discovery of many B-containing molecules is predicted, and these molecules 
will be useful in applications involving cell surface signalling (Bolanos et al. 2004; 
Redondo-Nieto et al., 2008). The main objective of this review is to reveal other promising 
research directions for B-based chemicals in chemoprevention and chemotherapy, 
particularly in breast cancer. 
2. Boron compounds in cancer prevention 
2.1 Dietary boron and cancer risk 
A diet with low B has been found to lead to a number of general health problems and to 
increase cancer risk. The most common symptoms of B deficiency include arthritis, 
memory loss, osteoporosis, degenerative and soft cartilage diseases, hormonal 
disequilibria and a drop in libido (Scorei & Popa, 2010). The daily uptake of B varies as a 
function of food selection, the use of some specific personal products and the water B 
content. Reported values for the overall B uptake vary as follows: 0.8-1.9 mg/day in the 
European Union, 1.7-7 mg/day in the United States, ~0.93 mg/day in Korea, 2.16-2.28 
mg/day in Australia, 1.75-2.12 mg/day in Mexico and 1.8-1.95 mg/day in Kenya (Rainey 
& Nyquist, 1998). These dissimilarities may be correlated with regional differences in the 
abundance of high-energy food and in food products rich in fibres and plant proteins. The 
actual B requirements for the human body remain unclear. Thus, more knowledge about 
the biological functions of B and the regulation of its exchange is required (Nielsen, 2009). 
The B Tolerable Upper Intake Level (UL) for adults of ~18 years is ~20 mg B per day 
(Scorei & Rotaru, 2011). 
2.1.1 Lung cancer 
The mortality due to lung cancer has reached higher values for men than for women (Espey 
et al., 2007). A negative correlation has been found between the amount of B intake and the 
incidence of lung cancer, although the underlying mechanism remains unclear (Meacham et 
al., 2007). Experimental evidence has shown that nutrition with some B-compounds (such as 
boric acid, borax and calcium fructoborate) has had anti-oxidant or/and anti-inflammatory 
consequences (Nielsen, 2000; Hunt, 1998; Scorei et al., 2005). Correlations exist between 
some lung cancers and 17-beta-estradiol, and the treatment includes 17-beta-estradiol-based 
Hormone Replacement Therapy (HRT) (Schabath et al., 2004). Dietary supplementation with 
B has been shown to increase the concentration of 17-beta-estradiol (Wang et al., 2008), 
mimic the HRT effect and, in the case of postmenopausal women, it may be used to decrease 
the cancer risks associated with low estrogen levels (Devirian & Volpe, 2003). Low dietary B 
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(alone or together with HRT) has been correlated with an increase in lung cancer risk for 
women (Mahabir et al., 2008). The reduction of lung cancer risk may involve estrogen 
receptor binding substrates, other than estrogen, including carcinogenic Polycyclic Aromatic 
Hydrocarbons (PAHs) from cigarette smoke condensate (Pike et al., 1999). Women with 
high dietary B intake and HRT users may present higher hormone levels that compete with 
cigarette smoke carcinogens for estrogen receptors. If this model is correct, increasing the B 
intake during HRT will also limit the carcinogenic potential of PAHs from cigarette smoke. 
Recently, the highest quartile of B intake has been confirmed to be associated with the 
lowest lung cancer risks for smokers, while the highest risk exists in smokers with low 
dietary B and no HRT (Mahabir et al., 2008). 
2.1.2 Prostate cancer 
Dietary B is inversely correlated with the occurrence of prostate cancer (Yan et al., 2004), 
even if the source of this correlation remains unclear. The prostate cancer risk was one third 
smaller for men ingesting more than 1.8 mg B per day from food, relative to only 0.9 mg 
B/day. A relatively high correlation (r = 0.63) was found between the B concentration from 
the subsurface water and the prostate cancer distribution in Texas (Barranco et al., 2007). A 
broader understanding of the cellular mechanisms that involve B have shown that boric acid 
(BA) inhibits prostate cancer cell growth by decreasing cyclin A-E expression, though B does 
not induce cell death (Barranco et al., 2009). Furthermore, cells treated with BA demonstrate 
diminished adhesion and migration, which indicates a low metastatic potential. B has been 
hypothesised to have effects on prostate cancers through its influence on steroid hormones 
(particularly androgens, which are involved in prostate carcinogenesis) (Gann et al., 1996). 
Three research directions have been followed to study the relationship between B and 
prostate cancer risk: steroid hormone regulation, anti-cancer metabolites and cell 
proliferation. Several potential BA binding sites may be involved in prostate cancer. For 
example, Prostate Serum Antigen (PSA), a serine protease, is a potential site for direct 
boration (Gallardo-Williams et al., 2003). Boric acid decreases the expression of five major 
cyclin proteins (A, B1, C, D1 and E), which have significant roles in the cell cycle (Barranco & 
Eckhert, 2006) and inhibit the release of Ca(II) stored by the NAD+cADPR system. This 
regulation of cyclins could explain the effects of B on prostate cancer cells. When B 
consumption was ~1.17 mg per day, no correlation with prostate cancer frequency was 
observed (Gonzalez et al., 2007). 
2.1.3 Cervical cancer 
Cervical cancer is the second most frequent cancer in women worldwide (Parkin et al., 
1993). The cause of this discrepancy is still unclear and can involve a combination of 
environmental, genetic, social and infectious factors. For example, Human papillomavirus 
(HPV) is the primary cause of cervical cancer. HPV 16 and HPV 18 are responsible for ~95% 
of cervical cancers. Many other factors also correlate with the incidence of cervical cancer 
(Ursin et al., 1996; Ylitalo et al., 1999; Castellsague et al., 2002). According to one hypothesis, 
the low cervical cancer incidence in Turkey correlates with its B-enriched soil (Sayli et al., 
2001; Simsek et al., 2003). Indeed, the ingestion of B via drinking water prevents cervical 
cancer risk (Korkmaz et al., 2007). This effect has been suggested to be due to the B 
interference chemistry in the life cycle of HPVs, but no correlation could be found regarding 
the incidence of oral cancers, which are also induced by HPVs. Serine protease inhibitors 
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have been found to reduce the immortalisation and transforming capacity of the HPV E7 
oncogene (Stoppler et al., 1996). Because B exists in the human body mostly in the form of 
BA, which is an inhibitor of serine proteases, ingestion of high amounts of B through 
drinking water has been hypothesised as able to inhibit HPV transformation, thus reducing 
the incidence of cervical cancer (Korkmaz et al., 2007). 
2.2 Dietary boron and breast cancer prevention 
Today, breast cancer is the most common cancer type diagnosed in women, excluding non-
melanoma skin cancers (Greenlee et al., 2000). Breast cancer is related to endogenous 
hormones. Many studies have linked breast cancer risk to the age of menarche, menopause 
and first pregnancy (Harris et al., 1992). Postmenopausal obesity has been observed to 
increase the risk (Stoll, 1998; Pujol et al., 1997), perhaps due to increased peripheral estrogen 
production. However, this relationship between weight and risk does not appear in 
premenopausal women (Kelsey, 1979). In fact, some studies have reported an inverse 
relationship between weight and risk at a younger age (Holmes et al., 1999). In Japan, breast 
cancer is a rare disease compared to the Western countries (Tominaga & Kuroishi, 1999). 
When Japanese women immigrated to the USA, they acquired the same risk for breast 
cancer as that in the general population of women in the USA (Probst-Hensch et al., 2000). 
This increased risk occurred due to environmental and dietary factors (Maskarinec et al., 
2001; Probst-Hensch et al., 2000). Proliferative breast disease has been observed more 
frequently in women with a significant family history of breast cancer (Vogel, 2000). A 
number of environmental factors have also been linked to breast cancer risk. Exposure to 
ionising radiation, whether after a nuclear explosion or during medical procedures, has 
clearly been demonstrated to correlate with an increase in the risk of breast cancer 
(Spiegelman et al., 1994). The risk level varies with the age of the subject. The risk was 
observed to be lower for exposures in the case of women over 40 years. The role of diet in 
the aetiology of the breast cancer seems to be extremely important. This importance has 
been suggested by the international variation in breast cancer incidence rates and by the 
observation that national per capita fat consumption correlates with breast cancer incidence 
and mortality (Armstrong & Doll, 1975). However, prospective studies regarding diet and 
breast cancer risk have failed to identify a relationship between dietary fat intake and breast 
cancer incidence during 10 years of follow-up (Hunter & Willett, 1996). The absence of a link 
between dietary fat intake and cancer risk within the context of a Western diet has been 
confirmed by a pooled analysis of seven cohort studies involving 337,816 women. The 
analysis has demonstrated no risk differences between women with the lowest and those 
with the highest quintile of fat intake (Hunter et al., 1996). However, all of these studies 
have addressed fat intake during adult life and do not exclude the possibility that fat intake 
during childhood and adolescence could subsequently influence breast cancer risk. Strong 
evidence exists that supports an association between alcohol and breast cancer. A meta-
analysis of 12 cases of control studies has demonstrated a relative risk (RR) of 1.4 for each 24 
g of alcohol consumed daily (Longnecker et al., 1988). However, defining a relationship 
between the age at which alcohol consumption began and breast cancer risk is difficult.  
2.2.1 Dietary boron intake, sex steroid hormones and breast cancer 
Several reports have indicated that 17-beta-estradiol levels increase with dietary boron 
supplementation in human subjects (Nielsen et al., 1987; Naghii & Samman, 1997). 
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Therefore, dietary boron might mimic the actions of Hormone Replacement Therapy (HRT). 
After one week, supplementation of healthy males with 10 mg B/day resulted in a 
significant rise in the plasma free testosterone concentration, which is an observation based 
on recent clinical data (Naghii et al., 2010). According to this recent study, the free 
testosterone level increases and the estradiol level decreases after short-term boron 
consumption. Breast cancer patients appear to have relative sex steroid hormone imbalance, 
in favour of estrogens (McTiernan et al., 2003). High bio-available testosterone counteracts 
the proliferative effects of estrogens on the mammary tissues and exerts a protective role to 
the breast, inhibiting cancer development and/or tumour growth (Hofling et al., 2007). 
However, preclinical studies have suggested that testosterone serves as a natural, 
endogenous protector of the breast. Worldwide data from prospective studies regarding the 
connection between the endogenous sex hormones levels and breast cancer risk in 
postmenopausal women have also shown multiple and complex relationships. Nine 
prospective studies of women who had not taken exogenous sex hormones when samples 
from their blood were collected for the determination of hormone levels have shown that 
the breast cancer risk increases significantly with an increased concentration of all examined 
sex hormones: total estradiol, free estradiol, non-sex hormone binding globulin (SHBG)–
bound estradiol, estrone, estrone sulphate, androstenedione, dehydroepiandrosterone, 
dehydroepiandrosterone sulphate and testosterone. High SHBG has been associated with a 
decrease in breast cancer risk (Dimitrakakis et al., 2010). Investigations regarding the 
association between premenopausal estrogen levels and breast cancer risk are complicated 
due to the cyclic estrogen variation during the menstrual cycle. The breast cancer risk 
among premenopausal women is directly related to the circulating levels of testosterone and 
androstenedione.  
In conclusion, daily dietary B intake at a minimum of 10 mg of B per day decreases the 
estradiol level and increases the testosterone level (Naghii et al., 2010). This regulation 
assures a true hormone-dependent protection against breast cancer. 
2.2.2 Boron, vitamin D and breast cancer 
Vitamin D is a steroid hormone that is synthesised in human skin from 7-
dehydrocholesterol in the presence of the UV light. Vitamin D is primarily metabolised in 
the liver and subsequently in the kidney in the form of calcitriol, the most biologically active 
metabolite of vitamin D (Zehnder et al., 2001; Tangpricha et al., 2001). In addition, 
epidemiologic, clinical and animal studies have demonstrated that vitamin D is important as 
a protective agent against the development of breast cancer (Buras et al., 1994; Mehta & 
Mehta, 2002). Boron has a role in energy substrate metabolism due to its involvement in 
vitamin D metabolism (Hegsted et al., 1991). Various boron-containing compounds have 
been discovered to be effective in transiently and acutely raising calcitriol levels to a 
significant degree in mammalian blood. Indeed, calcitriol levels could be increased almost 
80% upon the oral administration of a single dose of a boron-containing complex (15-20 mg 
boron as calcium fructoborate per day) (Pietrzkowski, 2010). Calcitriol in turn controls 
calcium and phosphate homeostasis and is essential for the development and maintenance 
of healthy bones. Calcitriol, or 1,25-DihydroxyvitaminD3, is the biologically active form of 
vitamin D and interacts with the Vitamin D Receptor (VDR). Calcitriol is a coordinate 
regulator of proliferation, differentiation and survival of breast cancer cell (Colston & 
Hansen, 2002). Therefore, vitamin D compounds that bind and activate VDRs have become 
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established therapeutic agents for breast cancer treatment. Various in vitro and in vivo 
studies have shown that vitamin D inhibits cell proliferation of a wide range of cell types, 
including carcinomas of the breast, prostate, colon, skin and brain, myeloid leukaemia cells 
and others (Mehta & Mehta, 2002; Ingraham et al., 2008). However, the processes mediating 
this inhibition have still not been entirely elucidated. Recently, vitamin D has been 
demonstrated to induce apoptosis and inhibit angiogenesis, tumour invasion and 
metastases. These preclinical data suggest that vitamin D (alone or in combination with 
other agents) has potential applications in cancer prevention and treatment. Low levels of 
plasma calcitriol have been associated with high rates of colorectal, breast, lung and prostate 
cancer incidence and mortality in men (Garland et al., 2006). The broad-spectrum anti-
tumour effects of calcitriol and its analogues are mostly based on the inhibition of cancer cell 
proliferation and invasiveness, induction of differentiation and apoptosis and promotion of 
angiogenesis.  
In a NHANES III (National Health and Nutrition Examination Survey III) cohort, Freedman 
has reported that women with serum calcitriol levels higher than 62 nmol/L present a 75% 
decrease in breast cancer mortality (Freedman et al., 2007). In two other studies, the authors 
have concluded that the breast cancer risk for women is 58% lower when vitamin D levels 
are higher than 95 nmol/L, in comparison with women with a calcitriol level lower than 
37.5 nmol/L (Simard et al., 1991; Bemd & Chang, 2002; Gissel et al., 2008). In a dose-
response meta-analysis, it has been reported that women with the highest calcitriol levels in 
their blood have a reduced breast cancer risk (Garland et al., 2006). In another study, 1760 
women were divided into 5 groups, from the lowest to the highest calcitriol levels (Garland 
et al., 2007). A dose-response association was evident. The highest breast cancer rates were 
found in the group with the lowest calcitriol levels (less than 32 nmol/L). The cancer rates 
were the lowest in women with serum calcitriol levels higher than 130 nmol/L. If the serum 
calcitriol levels are high enough, they reduce the breast cancer risk by 35%. Thus, boron 
could become an effective preventive diet for breast cancer by its action in inhibiting 
calcitriol degradation (Miljkovic, 2004).  
2.2.3 Boron, omega-3 fatty acids and breast cancer  
Laboratory animals subjected to a diet rich in both omega-3 fatty acids and boron 
demonstrate a high bone mineral density and their bones become stronger compared to 
animals fed with other dietary fats and boron. These findings suggest that omega-3 fatty 
acids and boron can work together to support dense, strong bones (Nielsen & Penland, 
2006). A diet rich in omega-3 α-linolenic acid promotes femur strength, especially when the 
dietary boron is adequate. In recent research studies, the bone health benefits of omega-3 
fatty acids have been discovered to be greatly amplified when these essential fats are 
combined with the critical trace of mineral boron (Nielsen, 2008). Intriguing new research 
findings have suggested that bone-supporting effects of boron can be the greatest when 
omega-3 fatty acids are available. For instance, as mentioned earlier, a diet rich in both 
omega-3 fatty acids and boron give laboratory animals higher bone mineral density and 
stronger bones in comparison to animals that are fed other fats.  
The association between ω-3 fatty acids and breast cancer risk has been examined in several 
studies (Rose & Connoly, 1993; Deckere, 1999; Saadatian et al., 2004). The results have 
demonstrated that this correlation varies according to the study design. A meta-analysis of 
biomarker studies based on three cohorts and seven case-control studies has found a 
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significant protective effect of total ω-3 PUFAs (Kim et al., 2009). At the same time, only an 
inverse association with a borderline significance for α-linolenic acid in case-control studies 
has been demonstrated (Fritsche & Johnston, 1990). However, according to a recent 
systematic review, only one study has shown a significantly increased breast cancer risk, 
three studies have presented a decreased risk and seven other studies have failed to 
demonstrate a significant relationship with ω-3 fatty acid intake (MacLean et al., 2006). In 
the UK, fish oil consumption has been associated with protection against breast 
carcinogenesis (Caygill et al., 1995; Caygill et al., 1996). A postmenopausal study, which 
took place in the USA, has found a significant inverse correlation between fish intake 
(canned, fried, fresh and shellfish) and breast cancer risk (Shannon et al., 2003). This 
investigation identified fish and fish ω-3 fatty acid intake as an important potential 
protective factor in the nutritional aetiology of breast cancer. Moreover, recent studies have 
shown that boron protects omega-3 fatty acids (Nielsen, 2004; Nielsen & Penland, 2006) and 
consequently, a diet rich in boron and omega-3 will ensure a low breast cancer risk for 
women, especially because boron stimulates calcitriol synthesis, an anti-tumour agent that 
has been extremely well studied during recent years.   
3. Boron-mediated chemoprevention of breast cancer 
Cancer chemoprevention uses natural, synthetic or biological chemical agents to reverse, 
suppress or prevent carcinogenic progression (Sporn & Suh, 2000). Epithelial carcinogenesis 
is a multi-step process in which an accumulation of genetic events within a single cell line 
leads to a progressively dysplastic cellular appearance, deregulated cell growth, and, finally, 
carcinoma. In fact, the initial proposed definition for chemoprevention strictly refers to 
cancer prevention with pharmacological agents that inhibit or reverse the carcinogenesis 
process. This concept differs from that of cancer prevention, which refers mostly to removal 
or avoidance of factors such as fat, tobacco or UV radiation (Malone et al., 1989). According 
to their mechanisms, chemopreventive agents are classified into two broad categories: 
effective compounds against complete carcinogens and effective compounds against tumour 
promoters. Some compounds belong to both categories. The inhibitors of carcinogen-
induced tumours are further divided in three major groups according to their different 
mechanisms of action. The first group includes agents that interfere with the precursor 
compounds of metabolic reactions, which are converted into carcinogens. The second group 
comprises agents capable of preventing carcinogens by reaching or reacting with target 
sites. This mechanism is realised by scavenging the reactive form of carcinogens. The third 
group includes molecules that have an inhibitory action following the exposure to 
carcinogenic agents. For this reason, these molecules are called suppressing agents. 
3.1 Boric acid  
Boric acid (BA) is one of the most studied B-containing chemicals. BA has been 
demonstrated to control the proliferation of some cancer cell types (Barranco et al., 2009; 
Barranco & Eckhert, 2006; Acerbo &Miller, 2009; Scorei et al., 2008). BA is an inhibitor of 
peptidases, proteases, proteasomes, arginase, nitric oxide synthase and transpeptidases 
(Bradke et al., 2008; Hunt, 1998). Inhibition of serine protease and dehydrogenase activities 
can be explained by the capacity of BA to bind OH groups from NAD and serine (Gallardo-
Williams et al., 2003). The Prostatic Serum Antigen (PSA) is a serine protease and a putative 
target for BA (Scorei & Popa, 2010). Based on the PSA inhibition, the use of BA in the 
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chemical therapy of prostate carcinoma has been proposed (Gallardo-Williams et al., 2003). 
BA inhibitory effects have also been found in androgen-independent cell lines (DU-145 and 
PC- 3l), suggesting that other (serine protease-independent) mechanisms could also exist 
(Barranco & Eckhert, 2006). BA inhibits the cell cycle control and proliferation of DU-145, 
acting against the agonist-stimulated release of Ca2+ from ryanodine receptor sensitive cell 
stores (Henderson et al., 2009). In the case of melanoma cells, BA slows down the 
proliferation, possibly by inhibiting the second step of pre-mRNA splicing (Shomron & Ast, 
2003). A high dose of BA (12.5–50 mM) slows cell replication and induces apoptosis in both 
melanoma cells and MDA231 breast cancer cells (Acerbo & Miller, 2009; Scorei et al., 2008). 
Thus, the inhibition of cancer cells by BA involves a diversity of cellular targets, such as 
direct enzymatic inhibition, apoptosis, receptor binding and mRNA splicing. 
Recently, 1 mM of BA has been experimentally demonstrated to inhibit the ZR-75-1 breast 
cancer cell line, but not the MCF-7 cell line (Meacham et al., 2010; Elegbede, 2007). The lack 
of BA-mediated inhibition of MCF-7 cellular growth could be due to the presence of the 
“sodium-boron co-transporter (NaBC1)”. This co-transporter exists on the cell surface and 
can pump out boron molecules from the cell in exchange for Na+ ions. This co-transporter is 
not present in ZR-75-1 cells. ZR-75-1 is a non-metastatic epithelial breast cancer cell line, 
which is estrogen receptor– and progesterone receptor–positive. MCF-7 is metastatic 
epithelial cell lines of breast cancer. These cells are positive for estrogen receptor and 
progesterone receptor. If BA becomes an anti-cancer agent for breast cancer, these data will 
encourage women with increased cancer risk factors to raise their boron intake to reduce 
their chance of developing this disease. 
3.2 Calcium fructoborate 
Calcium fructoborate (CF) is a natural product that is extracted from plants, but it can also 
be produced by chemical synthesis (Scorei & Popa, 2010). CF is efficient in the prevention 
and treatment (as adjuvant) of osteoporosis and osteoarthritis (Peng et al., 2000; Miljkovic et 
al., 2009; Scorei & Rotaru, 2011). In addition, CF has shown inhibitory effects on MDA-MB-
231 breast cancer cells (Scorei et al., 2008; Scorei & Rotaru, 2011). CF most likely enters the 
cell through a co-transport mechanism via a sugar transporter (Miljkovic et al., 2009). MBA-
MD-231 is a metastatic cancer cell line and is negative for expression of estrogen receptor. 
Inside cells, CF acts as an antioxidant and induces the over-expression of apoptosis-related 
proteins and eventually apoptosis. In our recent study, we have demonstrated that CF and 
BA inhibit the proliferation of MDA-MB-231 breast cancer cells in a dose-dependent manner 
(Scorei et al., 2008). As revealed by different experiments (TUNEL, Bcl-2 and pro-caspase-3 
protein expression and cytochrome c caspase-3 activities), the anti-proliferative effect of CF 
in MDA-MB-231 breast cancer cells appeared to be mediated by the induction of apoptosis. 
On the other hand, CF raises the calcitriol level in blood (Pietrzkowski, 2010), which induces 
apoptosis and inhibits angiogenesis, tumour invasion and metastasis of breast cancer cells. 
3.3 Boronic acid and its esters 
From the structural point of view, boronic acids are trivalent boron-containing organic 
compounds that possess one alkyl substituent (i.e., a C–B bond) and two hydroxyl groups to 
fill the remaining valences on the boron atom. Boronic acids are potent and selective 
inhibitors of cancer cell migration and viability. One potential mechanism of action is the 
inhibition of proteases. Due to the easy interconversion of boronic acids between the neutral 
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sp2 (trigonal planar substituted) and the anionic sp3 (tetrahedral substituted) hybridisation 
states, the B-OH unit replaces the C=O bond at a site where an acyl group transfer takes 
place (Groziak, 2001). Phenylboronic acid (PBA) and diphenylboronic esters (DPBE) are the 
most efficient types of boronic acid derivatives that act as serine protease inhibitors (Yang et 
al., 2003). PBA is more efficient than BA and decreases cancer cell viability in eight days. 
Non-tumorigenic cells are at least five times less sensitive to PBA at the effective dose for 
cancer cells. These data suggest that PBA could be a promising cancer treatment and could 
possibly be used prophylactically. Phenylboronic acid has more favourable in vitro 
properties than do other compounds (e.g., migrastatin and carboxyamido-triazole). PBA 
shows a selective inhibition of breast and prostate cancer migration in vivo and of tumour 
metastasis in mice (Bradke et al., 2008). The properties that phenylboronic acid shares with 
other anti-cancer drugs highlight the fact that it is more effective than BA for cancer 
chemoprevention (Groziak, 2001; Yang et al., 2003). 
4. Boron chemotherapy of breast cancer 
4.1 Bortezomib 
The drug Bortezomib (PS-341) (Teicher et al., 1999) is a boronic acid derivative and a 
proteasome inhibitor, which is a novel target in cancer therapy. This compound disrupts cell 
cycle regulation and induces apoptosis. Strong cytotoxic effects of PS-341 have been seen in 
prostate cancer cells and MCF-7 and EMT-6 breast carcinoma cells. In cell cultures, 
Bortezomib induces apoptosis in both haematologic and solid tumour malignancies, 
including myeloma, mantle cell lymphoma, cell lung cancer, ovarian cancer, pancreatic 
cancer, prostate cancer, breast cancer, and head and neck cancers (Palumbo et al., 2008; 
Adams et al., 1999; Boccadoro et al., 2005; MacLaren et al., 2001). A good correlation has 
been observed between the Bortezomib dose, proteasome inhibition and positive 
modulation of serum PSA. Bortezomib has been approved by the US Food and Drug 
Administration for the treatment of chemorefractory multiple myeloma patients (Kane et al., 
2003) and for some forms of non-Hodgkin's lymphoma (Goy et al., 2005). This inhibitor is 
still in clinical studies for multiple tumour types, including breast cancer (Boccadoro et al., 
2005; Dees et al., 2004; Cardoso et al., 2004; Codony-Servat, 2006). In a phase II trial, the 
Bortezomib efficacy in patients with metastatic breast cancer was evaluated (Albenell et al., 
2003). Although Bortezomib inhibits proteasome activity and reduces the circulating levels 
of IL6, these biological effects have not been associated with a meaningful clinical activity; 
no objective clinical response has been observed. Therefore, we do not recommend further 
investigations for Bortezomib as a single agent in the treatment of metastatic breast cancer 
(Yang et al., 2006). Until now, clinical experiments with Bortezomib have demonstrated only 
a limited activity against solid tumours when it is used as a single agent. However, 
Bortezomib could have a significant anti-tumour activity when it is used in combination 
with other active conventional agents (Agyin et al., 2009). Numerous trials using Bortezomib 
combination regimens are currently pending. Regarding breast cancer, the potential efficacy 
of Bortezomib with taxanes and anthracyclines is of particular interest. In a recent phase I 
trial that used Bortezomib together with docetaxel in anthracycline-pretreated advanced 
breast cancer, six of nine patients achieved partial response (Yang et al., 2006). In vitro and in 
vivo (murine xenograft) studies have revealed that Bortezomib is active against a variety of 
malignancies, including haematologic malignancies and solid tumours (i.e., breast, prostate, 
lung, pancreas, colon, ovarian, and head and neck cancers). Bortezomib has demonstrated 
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its activity as a single agent and in combination with several other cytotoxic agents, such as 
5-fluorouracil, irinotecan, gemcitabine, doxorubicin and docetaxel, and with radiation, 
enhancing both chemotherapy- and radiation therapy (RT)-induced apoptosis. Bortezomib 
has also shown activity in some cell lines resistant to standard therapies. Bortezomib has 
been demonstrated to decrease the survival of cultured MCF-7 cells derived from human 
breast cancer and of EMT-6 parent mouse mammary carcinoma xenograft tumours in a 
dose-dependent manner (Teicher et al., 1999). In addition, combinations of Bortezomib with 
anthracyclines have been investigated, proving the prominent role of these agents in breast 
cancer therapy. Using a BT-474–based xenograft model of human breast cancer, the 
researchers found that the combination of Bortezomib with liposomal doxorubicin enhances 
anti-tumour efficacy and increases apoptosis, compared with the results obtained using each 
agent alone (Orlowski & Dees, 2003). Recently, a new proteasome inhibitor has been 
designed and synthesised; this compound, named BU-32, is a bisdipeptidyl boronic acid, a 
Bortezomib analogue, that contains an additional dipeptide boronic acid moiety on the 
pyrazine ring to potentially achieve a stronger binding affinity and an increased potency 
(Agyin et al., 2009). Divalent proteasome inhibitors, either hetero-bivalent or homo-bivalent, 
have been reported to increase the potency of inhibition by two orders of magnitude 
compared to the monovalent analogues, although a linker of 18 to 22 carbon atoms typically 
separates the active moieties in these compounds. A novel diboronated Bortezomib 
analogue, named BU-32 (NSC D750499-S), has been shown to be a potent and selective 
inhibitor of the chymotrypsin-like activity of the 20S proteasome. This compound has in 
vitro anti-tumour activity against different breast cancer cells and in vivo efficacy in mouse 
xenograft and metastasis models.  
Paclitaxel (PAC), an anticancer drug, is used for the treatment of breast, ovarian, lung and 
head and neck cancer (Von Hoff, 1997; Rowinsky, 1997). However, this drug is known to 
cause adverse effects in different organs, such as heart and brain (Lachkar et al., 2006). 
Recently, results have clearly indicated that boron (as BA) supplementation to lymphocyte 
cultures ameliorates PAC-induced DNA damage (Turkez et al., 2010). BA plays a similar 
role in cancer patients after chemotherapy. However, specific protective agents for 
chemotherapy induce adverse effects after PAC or treatment with other anti-cancer drugs, 
although they should not interfere with the anti-tumour activity of the drugs (Pisano et al., 
2003). The in vivo BA and PAC interactions are still unknown. At this point, further in vivo 
investigations are necessary to justify boron daily intake to minimise the adverse effects of 
anti-cancer drugs. 
5. Mechanisms involving the activity of Boron compounds on cancer cells 
5.1 Boron cross-talk with calcitriol 
Assuming that boron and vitamin D are linked in a metabolic pathway, how does boron 
increase calcitriol levels? It seems unlikely that boron status would influence endogenous 
cholecalciferol synthesis, which is a nonenzymatic dermal reaction in which 7-
dehydrocholesterol, an intermediate in cholesterol synthesis, is cleaved by ultraviolet light 
and then undergoes a spontaneous rearrangement. On the contrary, it seems likely that 
boron either up-regulates the 25-hydroxylation step or suppresses the major pathway of 25-
OH-D catabolism, 24-hydroxylation (Miljkovic et al., 2004), giving the hypothesis that boron 
acts to suppress the latter reaction. Boron readily forms covalent complexes with cis-vicinal 
dihydroxy compounds. Thus, it is conceivable that boron can form such a complex with 
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24,25-dihydroxyvitamin D, the final product of the 25-OH-D reaction with 24-hydroxylase. 
Either this postulated complex acts as a competitive inhibitor for the 24-hydroxylase 
reaction, or, alternatively, acts to down-regulate the expression of this enzyme. Another 
possibility is that boron is a direct enzyme inhibitor at very modest concentrations. Indeed, 
boron can inhibit numerous enzymes, usually at supraphysiological concentrations (Hunt, 
1994). Testing these hypotheses in vitro are mandatory, using hepatocytes or other cells 
capable of expressing the 24-hydroxylase activity. Clinically, the testable implication of this 
hypothesis is that boron supplementation should increase 25-OH-D serum levels, while 
24,25-dihydroxyvitamin D serum levels remain constant or decline. This implication would 
strengthen the interesting possibility by which boron is a potent inhibitor for a range of 
microsomal enzymes, which catalyse the insertion of the hydroxyl group vicinal to the 
existing hydroxyl groups in steroids; specific examples of such enzymes are 24-hydroxylase 
and the estradiol hydroxylases (Miljkovic et al., 2004). Epidemiological studies have shown 
an inverse relationship between exposure to solar radiation and high breast cancer incidence 
and mortality (Garland et al., 1990; John et al., 1999). Another plausible link between 1,25-
(OH)2D3 and breast cancer has been uncovered by the observation that the 20q13.2 
chromosomal region, which contains 24-hydroxylase (CYP24), is amplified in breast cancer. 
Because 24-hydroxylase is involved in the degradation of 1,25-(OH)2D3, its amplification 
may lead to a decrease in 1,25-(OH)2D3 serum levels, thus providing a conducive 
microenvironment for cell growth in the absence of vitamin D-mediated growth control 
(Guryev et al., 2003). Furthermore, 1,25-(OH)2D3 serum levels have been found to be 
reduced to a greater extent in advanced bone metastatic breast cancer patients than in early 
stage patients (Mawer et al., 1997). The VDR is expressed in most breast cancer cell lines, 
carcinogen-induced rat mammary tumours, normal breast tissues and primary breast cancer 
tumours. Furthermore, increased RXR and VDR protein levels have been found in breast 
cancer tissues, compared with levels in normal breast tissues (Bortman et al., 2002; Friedrich 
et al., 2002). Several studies have demonstrated that a high proportion of breast cancer 
biopsy specimens contain vitamin D receptors (VDR) (Freake et al., 1984; Eisman et al., 1986; 
Berger et al., 1987). Moreover, an association between VDR levels and prognosis appears to 
exist; tumour receptor status has been positively related to disease-free survival (Colston et 
al., 1989; Berger et al., 1991).  
Several studies have indicated that the activation of the cell death pathway is an important 
aspect of the anti-tumour effects of vitamin D analogues in breast cancer cells. Further 
characterisations of the apoptosis-related genes, which are regulated directly or indirectly 
by vitamin D derivatives, will provide the basis for the design of new compounds able to 
target these pathways in breast cancer cells. Understanding how the apoptotic pathway, 
mediated by the vitamin D, can modulate or overlap with more-established pathways 
leading to cell death is likely to provide clinically useful information. When biologically 
active vitamin D is needed, 25(OH)D in the kidney is enzymatically converted to its active 
form, 1,25(OH)2D3 (calcitriol). This conversion is mediated by the 25(OH) vitamin D 1α-
hydroxylase, a cytochrome P450 protein, and 1,25(OH)2D3 is then conducted to the tissues. 
The actions of calcitriol in calcium homeostasis control of cell growth and differentiation, 
cell adhesion and apoptosis (controlled cell death) are mediated by its interaction with the 
VDR, which is a member of the nuclear receptor super-family (Thorne & Campbel, 2008). 
In a recent study (Liu et al., 2006), it was reported that one of the first observed responses 
upon infection of human monocytes with tuberculosis (M. tuberculosis) is the activation of 
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the cytochrome P450 enzyme encoded by the gene Cyp27B1, which converts vitamin D to its 
active form. When calcitriol is available for the cell, it is able to synthesise cathelicidin, an 
antimicrobial peptide that can destroy the tuberculosis bacteria. When calcitriol is not 
available, cathelicidin cannot be synthesised and the defence mechanism fails. The 
protective effects of calcitriol against the development of cancer are mainly due to its role in 
regulating the cell cycle (Gombart et al., 2005). Calcitriol and functional VDR are required 
for normal control of the cell cycle. Normal cell growth is controlled by regulating the levels 
and activity of cyclins and their dependent kinases. Calcitriol and boron affect the cyclin 
pathways by regulating gene expression of the proteins p27 and p21; the consequence of this 
regulation is inhibition of the cyclin dependent kinases (CDKs). Calcitriol and its active 
complexes interact with cyclin D and have a protective effect by blocking cell proliferation 
(Holick, 2007; Ingraham et al., 2008). 
5.2 Boron and proteasome inhibition 
The proteasome inhibitor, Bortezomib, exhibits anti-proliferative, pro-apoptotic, anti-
angiogenic and anti-tumour activities in several cancer models (Cardoso et al., 2004). The 
mechanism of action of Bortezomib involves the stabilisation of NF-κB, p21, p27, p53, Bid 
and Bax, the inhibition of caveolin-1 activation, the activation of JNK and the endoplasmic 
reticulum stress response (Boccadoro et al., 2005). These preclinical evaluations have 
revealed that Bortezomib is well tolerated at doses that demonstrate an anti-tumour activity 
in xenograft models of multiple myeloma, adult T-cell leukaemia, lung, breast, prostate, 
pancreas, head and neck, colon cancers and melanoma (Yang et al., 2003). The proteasome is 
an adenosine triphosphate (ATP)–dependent multi-catalytic protease that is present in the 
cytoplasm and the nucleus of all eukaryotic cells, from those in yeast to those in humans. 
The proteasome represents approximately 1% of the cellular proteins and is responsible for 
the non-lysosomal degradation of most intracellular proteins. The 26S proteasome consists 
of two functional entities: the 20S core catalytic complex and the 19S regulatory subunits. 
The proteasome has three catalytic activity types: chymotryptic-like, tryptic-like and 
caspase-like or postglutamyl cleavage activity. The boronic acid group forms a complex 
with the threonine hydroxyl group in the chymotrypsin-like active site and acts as a 
reversible inhibitor of the chymotryptic-like activity of the proteasome, which is sufficient to 
inhibit proteolysis (Boccadoro et al., 2005). In addition to the removal of damaged or 
unnecessary proteins, proteasome-mediated proteolysis is also an important mechanism for 
regulating the levels of some key regulatory proteins and their inhibitors. This regulation is 
crucial for controlling many cellular processes, including the activation of transcription 
factors, cell cycle progression, angiogenesis, cell adhesion, cytokine production and 
apoptosis. Many processes that rely on proteasome function contribute to the growth and 
survival of cancer cells. Thus, the critical role of the ubiquitin–proteasome pathway has led 
to the investigation of proteasome inhibition as a potential anti-cancer therapy 
(D’Alessandro et al., 2009). In cancer, the ubiquitin–proteasome pathway plays a number of 
important roles, including the regulation of tumour growth through multiple targets 
influencing cell cycle progression and apoptosis, cell adhesion, invasion and metastasis. The 
ubiquitin–proteasome pathway is also required for transcriptional regulation. Nuclear 
factor–κB (NF-κB) is a critical transcription factor involved in immune responses and 
cellular growth. Constitutive activation of NF-κB has been shown to be involved in the 
development of many human malignancies, including breast cancer (Cardoso et al., 2004).  
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NF-κB activation is regulated by the proteasome-mediated degradation of the IκB inhibitor 
protein. After IB degradation, NF-κB moves to the nucleus and regulates genes encoding 
cytokine-like tumour necrosis factor (TNF), interleukin (IL)–1, IL-2, and IL-630, pro-
inflammatory enzymes (nitric oxide synthase, cyclooxygenase-2), chemotactic factors (IL-8 
and the monocyte chemoattractant protein–1) and cell adhesion molecules, such as E-
selectin, intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 
(VCAM-1), which are involved in tumour metastasis and angiogenesis (Boccadoro et al., 
2005). NF-κB also regulates genes involved in the expression of anti-apoptotic proteins, such 
as members of the Bcl-2 and inhibitors of apoptosis families, which mediate resistance to 
chemotherapy and radiation therapy (RT) (Dong et al., 2002). Malignancies with high-
activated NF-κB levels, such as breast cancer, should be sensitive to the interruption of this 
pathway. The level of NF-κB in tumour cells is high in the estrogen receptor (ER)–negative 
human breast cancers. Inhibition of NF-κB activation has been suggested to be a potential 
therapeutic approach in such tumours (Ling et al., 2003). The ubiquitin–proteasome 
pathway is also involved in ER turnover and in the regulation of growth factor receptors 
such as HER2/neu and EGFR (Tikhomirov et al., 2000; Mimnaugh et al., 1996; Magnifico et 
al., 1998) and oncoproteins, such as c-fos/c-jun, c-myc and N-myc. Although proteasome 
inhibition stabilises or increases the levels of these growth factors, preclinical studies have 
demonstrated that this stabilisation does not lead to activation of proliferation or increases 
in tumour growth.  
6. Conclusion 
Many scientific data exist that have shown that boron is an essential microelement in animal 
cells. With the knowledge that borate linkages function in cell-to-cell adhesion, it has been 
hypothesised that boronates target structural glycoproteins located along the cytoskeleton-
plasma membrane-cell wall assembly. The latter are normally cross-linked by boron, and 
results confirm that boronates can indeed disrupt a boron-glycoprotein linkage. Therefore, 
any biological function of boron represents the result of its role as a cross-linking molecule. 
Deficiency of boron in the diet has been linked to several pathological conditions, including 
some forms of cancer, osteoporosis and osteoarthritis.  
Breast cancer affects many women all over the world and has a favourable prognosis when 
it is discovered in time (in its initial phase). Diets rich in boron could significantly reduce 
some cancer types, especially breast, prostate, lung and cervical forms of cancer. 
Discovering the role of boron in animal cell metabolism will have a great significance in the 
“war” against cancer. Establishing boron as an anti-cancer agent in breast cancer will 
encourage women with increased risk factors for this disease. Thus, these women will 
increase their intake of boron-rich food (i.e., avocado, broccoli, raisins and nuts) and dietary 
boron supplements to reduce their chance of developing this disease. 
The present paper highlights the role of boron in the prevention, chemoprevention and 
chemotherapy of some forms of cancer, including breast cancer.  
The major elements in breast cancer prevention, chemoprevention and chemotherapy with 
boron include: 
1. for prevention, keep a diet rich in boron (around 20 mg per day) and an adequate 4:1 
balance between omega-6 and omega-3 in nutrition; 
2. in chemoprevention, BA and CF are the main “fighters” against breast cancer. Based on 
experimental evidence, BA induces apoptosis in both melanoma cells and MDA231 
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breast cancer cells and inhibits growth of breast cancer cell lines, like ZR-75-1 cells. CF 
has shown inhibitory effects on MDA-MB-231 breast cancer cells. In addition, it raises 
the calcitriol level in blood, thus increasing the level of protection against the 
development of breast cancer;  
3. in chemotherapy, Bortezomib is a novel target in cancer therapy, being approved by the 
US Food and Drug Administration. It exhibits anti-proliferative, pro-apoptotic, anti-
angiogenic and anti-tumour activities in several cancer models, including breast cancer.  
In conclusion, even though the actual B requirements for the human body remain unclear 
and further researches are necessary, the amount of B in prevention and chemoprevention 
of breast cancer up to the ‘Tolerable Upper Intake Level’ (~ 20 mg B per day) is probable the 
adequate amount of boron in the body that might diminish the incidence of some forms of 
cancer, including breast cancer. However, it is compulsory to discover and develop new 
boron-containing compounds with anti-tumour activity. 
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